<DOC>
	<DOCNO>NCT01547546</DOCNO>
	<brief_summary>This open-label , multicenter , Phase I , dose-escalating study evaluate safety tolerability , pharmacokinetics , pharmacodynamics efficacy GDC-0084 patient progressive recurrent high-grade glioma . Stage 1 dose escalation part study . Stage 2 , patient receive GDC-0084 recommend dose future study .</brief_summary>
	<brief_title>A Study GDC-0084 Patients With Progressive Recurrent High-Grade Glioma</brief_title>
	<detailed_description />
	<mesh_term>Glioblastoma</mesh_term>
	<mesh_term>Glioma</mesh_term>
	<criteria>Adult patient , &gt; /= 18 year age Interval least 12 week completion adjuvant radiotherapy glioma study entry Karnofsky Performance Status &gt; /= 70 screening Confirmed measurable disease per RANO Adequate hematologic organ function Patients enrol Stage 1 : Histologically document recurrent progressive highgrade glioma ( WHO Grade IIIIV ) Prior treatment least one regimen glioma ( radiotherapy without chemotherapy Grade III glioma radiotherapy chemotherapy Grade IV glioma ) and/or consider candidate regimen know provide clinical benefit Patients enrol Stage 2 : Histologically document recurrent progressive glioblastoma ( WHO Grade IV glioma ) Prior treatment one two regimen glioblastoma ( initial regimen consist radiotherapy chemotherapy ) Treatment antitumor therapy ( approved experimental ) within 4 week prior initiation study drug Requirement anticoagulants warfarin warfarinderivative anticoagulant ; lowmolecularweight heparin permit Any contraindication MRI examination Evidence Grade &gt; /= 1 intracranial hemorrhage Active congestive heart failure ventricular arrhythmia require medication Clinically significant history liver disease , include viral hepatitis , current alcohol abuse cirrhosis Unresolved toxicity prior therapy exception lymphopenia ( patient prior temozolomide ) alopecia Pregnant lactating woman</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>